MCID: OVR044
MIFTS: 46

Ovarian Carcinosarcoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Carcinosarcoma

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 20 58 15 17
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 20 58
Malignant Mixed Mullerian Tumor of the Ovary 20 58
Ovarian Malignant Mixed Mullerian Tumor 12 58
Mmmt of the Ovary 20 58
Malignant Mixed Müllerian Tumor of the Ovary 20
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Müllerian Tumor 20
Carcinosarcoma of Ovary 70
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6170
NCIt 50 C9192
SNOMED-CT 67 702368000
ICD10 via Orphanet 33 C56
UMLS via Orphanet 71 C0392998
Orphanet 58 ORPHA213512
UMLS 70 C0392998

Summaries for Ovarian Carcinosarcoma

GARD : 20 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood. Treatment usually consists of surgery to remove the tumor and chemotherapy. The chance of recovery and long-term survival ( prognosis ) is poor, with a reported 5-year survival rate of about 28%.

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to carcinosarcoma and mature teratoma. An important gene associated with Ovarian Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Carboplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and small intestine, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Related Diseases for Ovarian Carcinosarcoma

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 31.2 TP53 PIK3CA ERBB2
2 mature teratoma 30.2 TP53 H2AC18 ERBB2
3 papillary adenocarcinoma 30.0 TP53 ERBB2 BRCA1
4 bilateral breast cancer 29.8 TP53 PIK3CA ERBB2 BRCA1
5 vulva cancer 29.6 TP53 PIK3CA ERBB2 CD274
6 myeloma, multiple 29.4 TP53 PIK3CA H2AC18 ERBB2 CD274
7 uterine carcinosarcoma 29.3 TP53 PIK3CA ERBB2 CD274 BRCA1
8 rhabdomyosarcoma 29.3 TP53 PIK3CA ERBB2 CD274 BRCA1
9 adenocarcinoma 29.2 TP53 PIK3CA ERBB2 BRCA1
10 cystadenocarcinoma 29.2 TP53 PIK3CA ERBB2 BRCA1
11 serous cystadenocarcinoma 29.1 TP53 PIK3CA ERBB2 BRCA1 ARID1A
12 ovary adenocarcinoma 28.7 TP53 PIK3CA H2AC18 ERBB2 BRCA1 ARID1A
13 ovarian mesodermal adenosarcoma 11.1
14 gastric papillary adenocarcinoma 10.3 TP53 ERBB2
15 rare tumor 10.3
16 apocrine adenosis of breast 10.3 TP53 ERBB2
17 parotid gland cancer 10.3 TP53 ERBB2
18 comedo carcinoma 10.3 TP53 ERBB2
19 lung non-squamous non-small cell carcinoma 10.2 ERBB2 CD274
20 breast sarcoma 10.2 TP53 ERBB2
21 breast malignant phyllodes tumor 10.2 TP53 ERBB2
22 pleomorphic adenoma carcinoma 10.2 TP53 ERBB2
23 gastroesophageal junction adenocarcinoma 10.2 ERBB2 CD274
24 inguinal hernia 10.2
25 esophageal adenosquamous carcinoma 10.2 TP53 ERBB2
26 localized osteosarcoma 10.2 TP53 ERBB2
27 breast juvenile papillomatosis 10.2 PIK3CA ERBB2
28 endodermal sinus tumor 10.2
29 glioblastoma 10.2
30 fibrosarcoma 10.2
31 ganglioneuroblastoma 10.2
32 medulloepithelioma 10.2
33 ependymoblastoma 10.2
34 granulosa cell tumor of the ovary 10.2 TP53 ERBB2
35 breast papillomatosis 10.2 PIK3CA ERBB2
36 mixed oligodendroglioma-astrocytoma 10.2 TP53 CD274
37 intraductal breast benign neoplasm 10.2 PIK3CA ERBB2
38 ethmoid sinus adenocarcinoma 10.2 PIK3CA ERBB2
39 microglandular adenosis 10.2 TP53 ERBB2
40 ovarian epithelial cancer 10.2
41 exanthem 10.2 H2AC18 ERBB2 CD274
42 cauda equina syndrome 10.2
43 penile benign neoplasm 10.1 TP53 PIK3CA
44 parameningeal embryonal rhabdomyosarcoma 10.1 TP53 PIK3CA
45 teratoma 10.1
46 fallopian tube endometrioid adenocarcinoma 10.1 ERBB2 ARID1A
47 salivary gland disease 10.1 TP53 H2AC18 ERBB2
48 malignant spiradenoma 10.1 TP53 PIK3CA
49 thymus gland disease 10.1 TP53 H2AC18 CD274
50 thymus cancer 10.1 TP53 H2AC18 CD274

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma

Symptoms & Phenotypes for Ovarian Carcinosarcoma

GenomeRNAi Phenotypes related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.66 BRCA1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.66 BRCA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.66 ERBB2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.66 ARID1A BRCA1 ERBB2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.66 ARID1A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.66 ARID1A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.66 ARID1A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.66 BRCA1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.66 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.66 BRCA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.66 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.66 ERBB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 ARID1A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.66 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.66 ERBB2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.66 ARID1A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.66 H2AC18
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.66 ERBB2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.66 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.66 H2AC18

MGI Mouse Phenotypes related to Ovarian Carcinosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ARID1A BRCA1 ERBB2 PIK3CA TACSTD2 TP53

Drugs & Therapeutics for Ovarian Carcinosarcoma

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
4
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
5
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
6
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
7
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
8
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Tubulin Modulators Phase 3
11 Antimitotic Agents Phase 3
12 Angiogenesis Inhibitors Phase 3
13
Liposomal doxorubicin Phase 2, Phase 3 31703
14 Albumin-Bound Paclitaxel Phase 2, Phase 3
15 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
16 Gastrointestinal Agents Phase 3
17 Neurotransmitter Agents Phase 3
18 Dermatologic Agents Phase 3
19
Histamine Phosphate Phase 3 51-74-1 65513
20 Histamine H1 Antagonists Phase 3
21 Histamine Antagonists Phase 3
22 Anti-Allergic Agents Phase 3
23
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
24
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
25 Immunologic Factors Phase 2
26 Anti-Infective Agents Phase 2
27 Immunosuppressive Agents Phase 2
28 Antiviral Agents Phase 2
29 Antimetabolites Phase 2
30 Antibiotics, Antitubercular Phase 1, Phase 2
31 Anti-Bacterial Agents Phase 1, Phase 2
32 Alkylating Agents Phase 2
33 Immunotoxins Phase 1
34 Cola

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 A Randomised Feasibility Study of Extended Chemotherapy With Neoadjuvant Carboplatin, Then Surgery Followed by Adjuvant Paclitaxel and Gemcitabine Verses Neoadjuvant Gemcitabine and Carboplatin, Then Surgery, Followed by Adjuvant Paclitaxel Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
5 Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
6 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
7 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
8 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Active, not recruiting NCT02993705 Phase 2 Trabectedin
9 A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma Withdrawn NCT04149275 Phase 2 Cabozantinib;Ipilimumab;Nivolumab
10 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
11 Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing Completed NCT00066651 Phase 1
12 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514

Search NIH Clinical Center for Ovarian Carcinosarcoma

Genetic Tests for Ovarian Carcinosarcoma

Anatomical Context for Ovarian Carcinosarcoma

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

40
Ovary, Lymph Node, Small Intestine, Cervix

Publications for Ovarian Carcinosarcoma

Articles related to Ovarian Carcinosarcoma:

(show top 50) (show all 108)
# Title Authors PMID Year
1
Ovarian Carcinosarcoma with Retroperitoneal Para-Aortic Lymph Node Dissemination Followed by an Unusual Postoperative Complication: A Case Report with a Brief Literature Review. 61
33322259 2020
2
Surgical management of ovarian carcinosarcoma with inferior vena cava extension into the right atrium. 61
33391655 2020
3
Carcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma. 61
33216290 2020
4
Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases. 61
33115531 2020
5
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. 61
32029291 2020
6
Detailed overview on rare malignant ovarian tumors. 61
32115180 2020
7
Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary. 61
31796530 2020
8
Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience. 61
31766630 2019
9
Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube. 61
30913944 2019
10
A rare case of ovarian carcinosarcoma with squamous cell carcinoma. 61
30947745 2019
11
Ovarian carcinosarcoma: Current developments and future perspectives. 61
30771873 2019
12
Ovarian Teratoid Carcinosarcoma Is an Aggressive Tumor of Probable Mullerian Derivation with a Carcinosarcomatous and Mixed Germ-Cell Morphology. 61
31011323 2019
13
Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study. 61
30640703 2019
14
Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver. 61
30139533 2018
15
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. 61
29488261 2018
16
Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. 61
29143144 2018
17
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. 61
29426293 2018
18
Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. 61
30022854 2018
19
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. 61
30147940 2018
20
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. 61
30345126 2018
21
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. 61
28679774 2017
22
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. 61
28790096 2017
23
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. 61
28791266 2017
24
KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. 61
28032649 2017
25
Extremely Locally Advanced Ovarian Malignant Mixed Mullerian Tumor in 37-Years-Old Female. 61
28593890 2017
26
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. 61
27958685 2017
27
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. 61
28125702 2017
28
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. 61
27819640 2016
29
"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities". 61
27321238 2016
30
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. 61
27107722 2016
31
[SURGICAL TREATMENT OF OVARIAN CARCINOSARCOMA THAT DEVELOPED IN GIANT CYSTIC TERATOMA]. 61
27244929 2016
32
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. 61
27807494 2016
33
The Use of Lattice Radiation Therapy (LRT) in the Treatment of Bulky Tumors: A Case Report of a Large Metastatic Mixed Mullerian Ovarian Tumor. 61
26719832 2015
34
Carcinosarcoma of ovary with its various immunohistochemical expression: Report of a rare case. 61
26881579 2015
35
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. 61
26474755 2015
36
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. 61
27418786 2015
37
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. 61
25962155 2015
38
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. 61
25802693 2015
39
Expression of adhesion molecules and the proliferative activity of carcinosarcoma of the ovary. 61
25503171 2014
40
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. 61
25341582 2014
41
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. 61
26052208 2014
42
Extravascular migratory metastasis in gynaecological carcinosarcoma. 61
24734932 2014
43
Prolonged survival of a patient with pelvic recurrence of ovarian malignant mixed mullerian tumor after chemoradiotherapy. 61
25593719 2014
44
[A case and literature review of ovarian carcinosarcoma with long-term survival after repeated recurrences]. 61
25132040 2014
45
[Primary ovarian carcinosarcoma. Report of eight cases]. 61
25102674 2014
46
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. 61
24631447 2014
47
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. 61
24971408 2014
48
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. 61
24587930 2014
49
Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. 61
23906658 2013
50
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. 61
23926191 2013

Variations for Ovarian Carcinosarcoma

Cosmic variations for Ovarian Carcinosarcoma:

9 (show top 50) (show all 514)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90140159 TRAF7 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.1732G>A p.E578K 16:2175939-2175939 15
2 COSM144158749 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.512T>A p.L171H 17:7673539-7673539 15
3 COSM144315379 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 15
4 COSM111836164 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 15
5 COSM144651337 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 15
6 COSM142559914 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.407G>A p.R136H 17:7675088-7675088 15
7 COSM145019014 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.598A>G p.N200D 17:7674248-7674248 15
8 COSM122762842 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.94A>G p.K32E 17:7675122-7675122 15
9 COSM87900846 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.380C>T p.S127F 17:7675232-7675232 15
10 COSM121875541 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.422G>A p.R141H 17:7673802-7673802 15
11 COSM122734335 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.337G>A p.G113S 17:7674230-7674230 15
12 COSM87898527 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.814G>A p.V272M 17:7673806-7673806 15
13 COSM144658149 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.287G>A p.C96Y 17:7675208-7675208 15
14 COSM143944147 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.265C>T p.R89W 17:7674221-7674221 15
15 COSM142838949 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.380C>T p.S127F 17:7675232-7675232 15
16 COSM144148837 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-55C>T p.? 17:7675189-7675189 15
17 COSM143158810 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.-98C>T p.? 17:7675232-7675232 15
18 COSM105654789 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 15
19 COSM143943941 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.337G>A p.V113M 17:7673806-7673806 15
20 COSM143156843 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.266G>A p.R89Q 17:7674220-7674220 15
21 COSM121875983 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347G>A p.R116Q 17:7674220-7674220 15
22 COSM87897711 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.818G>A p.R273H 17:7673802-7673802 15
23 COSM121876485 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.421C>T p.R141C 17:7673803-7673803 15
24 COSM142837497 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 15
25 COSM93183877 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 15
26 COSM122299085 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.94A>G p.K32E 17:7675122-7675122 15
27 COSM121876255 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.315G>A p.M105I 17:7674252-7674252 15
28 COSM143370575 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.701G>A p.R234H 17:7673802-7673802 15
29 COSM111758775 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 15
30 COSM93183281 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.818G>A p.R273H 17:7673802-7673802 15
31 COSM106053434 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.742C>T p.R248W 17:7674221-7674221 15
32 COSM112282360 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 15
33 COSM144087235 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.234G>A p.M78I 17:7674252-7674252 15
34 COSM144651292 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.697G>A p.V233M 17:7673806-7673806 15
35 COSM143371076 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 15
36 COSM106080940 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.490A>G p.K164E 17:7675122-7675122 15
37 COSM106124583 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.423C>T p.C141= 17:7675189-7675189 15
38 COSM144015546 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347C>T p.S116F 17:7675232-7675232 15
39 COSM142846805 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.725G>C p.C242S 17:7674238-7674238 15
40 COSM122734300 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.418G>A p.V140M 17:7673806-7673806 15
41 COSM142560476 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 15
42 COSM145017865 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.616G>A p.G206S 17:7674230-7674230 15
43 COSM121876163 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.418G>A p.V140M 17:7673806-7673806 15
44 COSM143372002 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.598A>G p.N200D 17:7674248-7674248 15
45 COSM106053362 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.733G>A p.G245S 17:7674230-7674230 15
46 COSM145017944 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.625C>T p.R209W 17:7674221-7674221 15
47 COSM144312115 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.263C>T p.S88F 17:7675232-7675232 15
48 COSM142837469 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.814G>A p.V272M 17:7673806-7673806 15
49 COSM105619828 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.782+379G>A p.? 17:7673802-7673802 15
50 COSM122271559 TP53 ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour c.347G>A p.R116Q 17:7674220-7674220 15

Expression for Ovarian Carcinosarcoma

Search GEO for disease gene expression data for Ovarian Carcinosarcoma.

Pathways for Ovarian Carcinosarcoma

GO Terms for Ovarian Carcinosarcoma

Biological processes related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of reactive oxygen species metabolic process GO:2000378 8.96 TP53 BRCA1
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 TP53 BRCA1

Sources for Ovarian Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....